ELLEN DOYLE: Open Payments
NPI 1942872056 · MYRTLE BEACH, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,262 in 220 payments from 20 companies in 2025. Trend: 2023 $2,017 · 2024 $1,655 · 2025 $4,262
Food & beverage: $4,262
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 70 | $1,410 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 22 | $396 |
| Janssen Biotech, Inc. | 21 | $322 |
| GENZYME CORPORATION | 10 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $261 |
| Lilly USA, LLC | 13 | $223 |
| Gilead Sciences, Inc. | 8 | $182 |
| Madrigal Pharmaceuticals | 9 | $166 |
| Phathom Pharmaceuticals, Inc. | 8 | $164 |
| Ardelyx, Inc. | 11 | $162 |
Products named: SKYRIZI, DUPIXENT, TREMFYA, XIFAXAN, RINVOQ, ENTYVIO, OMVOH, MAVYRET.
Industry payments across SC — which companies pay providers there.
